Top Analysts Recommend 3 Strong Buy Stocks for June 2025
Wall Street's top analysts have identified Eli Lilly (LLY) and Solid Biosciences (SLDB) as standout buys with significant upside potential. Lilly, a pharmaceutical leader in diabetes and neurology treatments, carries a 26.42% projected gain according to BMO Capital's $900 price target. Nine of ten analysts rate it a Buy.
Meanwhile, gene therapy pioneer Solid Biosciences attracts bullish sentiment from Truist Financial. Both picks reflect growing institutional confidence in healthcare innovation—a sector increasingly drawing crossover interest from crypto investors seeking real-world asset exposure.